{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fidpodcast.simplecast.com%2Fepisodes%2Fusing-lipoglycopeptides-IZuvLojC","width":444,"version":"1.0","type":"rich","title":"Long-Acting Lipoglycopeptides for Skin and Soft Tissue Infections : Implementation Into Practice","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/447e44e7-9d72-420c-9b67-7ae517ccc5cd/id-lyl-prp5966-pod678-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/3d3f9903-6c80-44b7-9bd8-13557591db5e\" height=\"200\" width=\"100%\" title=\"Long-Acting Lipoglycopeptides for Skin and Soft Tissue Infections : Implementation Into Practice\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Hear Kyle Molina, PharmD, BCIDP, discuss key considerations to ensure successful implementation of long-acting lipoglycopeptides for ABSSSI treatment into practice, such as justifying cost, targeting the right patient population, selecting between infusion locations, and maximizing institutional impact."}